Medical Sector
Egyptian United Group for Pharmaceutical Industries
EGPI is a pharmaceutical manufacturing company founded in 2006 as a sister company to EGD, the Egyptian Group for Pharmaceutical Trading, established in 1994 as a marketing company for manufacturing, registering, and producing high-quality pharmaceutical products. Initially focused on the Egyptian market, EGPI has a vision to expand across the Middle East.
EGPI seeks to leverage its knowledge, experience, and licenses to utilize its strong production and marketing capabilities in the Middle East region for mutual benefit. EGPI’s advanced Research and Development department is a key to its success, equipped with state-of-the-art research techniques, information resources, and databases, featuring experienced pharmacists and chemists of high competence, allowing us to enhance our product portfolio.
Currently, EGPI has a wide portfolio comprising over 150 products covering a broad range of therapeutic categories. EGPI consists of ten magnetic divisions, supported by more than 450 dedicated employees.
Business Scope
Diverse
Andrology
Central Nervous System
Cosmetics
Vitamins and Dietary Supplements
Allergy Medications
Musculoskeletal System
Digestive System
Anti-Infectives
Endocrine Glands
Women's Health and Obstetrics
Pediatric Care
Respiratory System
Dermatological Diseases
Cardiovascular System
Arwan Saudi Pharmaceutical Industries
Arwan Pharmaceutical Industries, a Lebanese joint-stock company, was founded in 2009 by Mr. Abdel Razzaq Youssef as the founder and Dr. Rouida Daham as the co-founder. It is owned by a group of committed Lebanese and non-Lebanese professionals. The company commenced operations in 2013 with a primary manufacturing unit for injectable solutions. The first phase of the project is in progress, with expected future phases in the near future.
Arwan develops, manufactures, and markets critical care products, with a focus on a range of products such as next-generation anti-infectives, iron solutions, analgesics, antipyretics, digestive drugs, oncology treatments, asthma medications, cardiovascular drugs, osteoporosis treatments, and wound management.
To reduce time gaps and expedite market presence, Arwan collaborates with leading European companies, where production adds value to Arwan in the fields of anti-infectives, analgesics, cardiovascular drugs, antipsychotics, and asthma medications. Facilities and processes approved by EMEA and/or the US Food and Drug Administration enhance Arwan’s diligent efforts to achieve quality.